493,520 Shares in Haemonetics Corporation $HAE Acquired by Norges Bank

Norges Bank acquired a new stake in Haemonetics Corporation (NYSE:HAE) during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 493,520 shares of the medical instruments supplier’s stock, valued at approximately $36,822,000.

Several other institutional investors have also modified their holdings of the company. Quarry LP grew its stake in shares of Haemonetics by 63.4% during the first quarter. Quarry LP now owns 495 shares of the medical instruments supplier’s stock worth $31,000 after purchasing an additional 192 shares in the last quarter. GAMMA Investing LLC raised its stake in Haemonetics by 59.4% in the second quarter. GAMMA Investing LLC now owns 443 shares of the medical instruments supplier’s stock valued at $33,000 after buying an additional 165 shares in the last quarter. UMB Bank n.a. lifted its holdings in Haemonetics by 91.7% during the 2nd quarter. UMB Bank n.a. now owns 669 shares of the medical instruments supplier’s stock worth $50,000 after buying an additional 320 shares during the last quarter. Elevation Point Wealth Partners LLC acquired a new position in shares of Haemonetics during the 2nd quarter worth about $64,000. Finally, Parkside Financial Bank & Trust increased its holdings in shares of Haemonetics by 11.6% in the 2nd quarter. Parkside Financial Bank & Trust now owns 1,461 shares of the medical instruments supplier’s stock valued at $109,000 after acquiring an additional 152 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. Raymond James Financial restated an “outperform” rating and set a $90.00 target price on shares of Haemonetics in a research note on Friday, November 14th. BTIG Research reissued a “buy” rating and set a $88.00 price objective on shares of Haemonetics in a report on Friday, November 21st. Barrington Research upped their target price on shares of Haemonetics from $86.00 to $90.00 and gave the company an “outperform” rating in a report on Friday, November 7th. Needham & Company LLC lifted their price target on shares of Haemonetics from $68.00 to $78.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Finally, Wall Street Zen raised shares of Haemonetics from a “hold” rating to a “buy” rating in a research report on Saturday. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Haemonetics currently has a consensus rating of “Moderate Buy” and a consensus target price of $79.70.

Haemonetics Stock Performance

Shares of Haemonetics stock opened at $83.98 on Monday. The firm’s fifty day simple moving average is $61.83 and its 200-day simple moving average is $63.78. Haemonetics Corporation has a 12 month low of $47.31 and a 12 month high of $85.23. The stock has a market capitalization of $3.93 billion, a price-to-earnings ratio of 24.56, a PEG ratio of 1.51 and a beta of 0.29. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.64 and a quick ratio of 1.03.

Haemonetics (NYSE:HAE) last issued its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.12 by $0.15. The company had revenue of $327.32 million for the quarter, compared to the consensus estimate of $311.61 million. Haemonetics had a net margin of 12.67% and a return on equity of 27.22%. Haemonetics’s revenue for the quarter was down 5.3% on a year-over-year basis. During the same period last year, the firm posted $1.12 EPS. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. As a group, equities analysts forecast that Haemonetics Corporation will post 4.55 earnings per share for the current year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.